Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 2/20 | 1.00 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 8/20 | 0.68 |
| ▸ | NPC1 | O15118 | 7/20 | 0.68 |
| ▸ | RAB9A | P51151 | 7/20 | 0.68 |
| ▸ | MAPT | P10636 | 5/20 | 0.68 |
| ▸ | HTT | P42858 | 4/20 | 0.68 |
| ▸ | TP53 | P04637 | 2/20 | 0.68 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.62 |
| ▸ | SCN4A | P35499 | 1/20 | 0.54 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.54 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.48 |
| ▸ | FSCN1 | Q16658 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.47 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2706157 | 0.87 | TDP1 (0.77) | TDP1L3MBTL1SMN1; SMN2NPC1RAB9A | |
| SCHEMBL14375385 | 0.86 | TDP1 (0.75) | TDP1L3MBTL1SMN1; SMN2NPC1RAB9A | |
| SCHEMBL11108189 | 0.82 | MAPT (0.69) | TDP1L3MBTL1SMN1; SMN2NPC1RAB9A | |
| SCHEMBL26691598 | 0.81 | TDP1 (0.68) | TDP1L3MBTL1SMN1; SMN2NPC1RAB9A | |
| SCHEMBL22208955 | 0.81 | TDP1 (0.68) | TDP1L3MBTL1SMN1; SMN2NPC1RAB9A | |
| SCHEMBL22209093 | 0.81 | TDP1 (0.68) | TDP1L3MBTL1SMN1; SMN2NPC1RAB9A | |
| SCHEMBL22224082 | 0.81 | TDP1 (0.68) | TDP1L3MBTL1SMN1; SMN2NPC1RAB9A | |
| SCHEMBL26691573 | 0.81 | TDP1 (0.68) | TDP1L3MBTL1SMN1; SMN2NPC1RAB9A | |
| SCHEMBL7285684 | 0.81 | RAB9A (1.00) | TDP1L3MBTL1SMN1; SMN2NPC1RAB9A | |
| SCHEMBL11109981 | 0.81 | MAPT (0.68) | TDP1L3MBTL1SMN1; SMN2NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250179008-A1 | ANTIBACTERIAL AGENTS | TAXIS PHARMACEUTICALS, INC. (US) | 2025-06-05 | — | — | US | disclosed |
| US-20150191420-A1 | ANTIBACTERIAL AGENTS | TAXIS PHARMACEUTICALS, INC. | 2015-07-09 | — | — | US | disclosed |
| US-20150191420-A1 | ANTIBACTERIAL AGENTS | TAXIS PHARMACEUTICALS, INC. | 2015-07-09 | — | — | US | disclosed |
| US-20150191420-A1 | ANTIBACTERIAL AGENTS | TAXIS PHARMACEUTICALS, INC. | 2015-07-09 | — | — | US | disclosed |
| US-8865736-B2 | Antibacterial agents | Biota Scientific Pty Ltd (AU) | 2014-10-21 | — | — | US | disclosed |
| US-8865736-B2 | Antibacterial agents | Biota Scientific Pty Ltd (AU) | 2014-10-21 | — | — | US | disclosed |
| US-8865736-B2 | Antibacterial agents | Biota Scientific Pty Ltd (AU) | 2014-10-21 | — | — | US | disclosed |
| EP-1706398-B1 | Amino-benzazoles as P2Y1 receptor inhibitors | BRISTOL MYERS SQUIBB CO (US) | 2014-05-21 | — | — | EP | disclosed |
| US-20130072520-A2 | ANTIBACTERIAL AGENTS | BIOTA SCIENTIFIC MANAGEMENT PTY LTD (AU) | 2013-03-21 | — | — | US | disclosed |
| US-20130072520-A2 | ANTIBACTERIAL AGENTS | BIOTA SCIENTIFIC MANAGEMENT PTY LTD (AU) | 2013-03-21 | — | — | US | disclosed |
| US-20100173933-A1 | ANTIBACTERIAL AGENTS | PROLYSIS LTD (GB) | 2010-07-08 | — | — | US | disclosed |
| US-20100173933-A1 | ANTIBACTERIAL AGENTS | PROLYSIS LTD (GB) | 2010-07-08 | — | — | US | disclosed |
| US-20100173933-A1 | ANTIBACTERIAL AGENTS | PROLYSIS LTD (GB) | 2010-07-08 | — | — | US | disclosed |
| US-7470712-B2 | Amino-benzazoles as P2Y1 receptor inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-12-30 | — | — | US | disclosed |
| US-7470712-B2 | Amino-benzazoles as P2Y1 receptor inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-12-30 | — | — | US | disclosed |
| EP-1996180-A1 | ANTIBACTERIAL AGENTS | Prolysis Limited (GB) | 2008-12-03 | — | — | EP | disclosed |
| US-20080275090-A1 | AMINO-BENZAZOLES AS P2Y1 RECEPTOR INHIBITORS WITH PYRIDINE RING AND HETEROCYCLIC COMPONENTS | BRISTOL-MYERS SQUIBB COMPANY | 2008-11-06 | — | — | US | disclosed |
| US-20080275090-A1 | AMINO-BENZAZOLES AS P2Y1 RECEPTOR INHIBITORS WITH PYRIDINE RING AND HETEROCYCLIC COMPONENTS | BRISTOL-MYERS SQUIBB COMPANY | 2008-11-06 | — | — | US | disclosed |
| WO-2007107758-A1 | ANTIBACTERIAL AGENTS | PROLYSIS LTD (GB) | 2007-09-27 | — | — | WO | disclosed |
| WO-2007107758-A1 | ANTIBACTERIAL AGENTS | PROLYSIS LTD (GB) | 2007-09-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130072520-A2 | ANTIBACTERIAL AGENTS | ALK, ROS1, NOX1 | TDP1 3078/4885L3MBTL1 703/4885SMN1; SMN2 1208/4885 |
| US-20150191420-A1 | ANTIBACTERIAL AGENTS | ALK, ARG1, ROS1 | TDP1 2148/4885L3MBTL1 377/4885SMN1; SMN2 2959/4885 |
| US-20250179008-A1 | ANTIBACTERIAL AGENTS | ALK, ROS1, NOX1 | TDP1 3078/4885L3MBTL1 703/4885SMN1; SMN2 1208/4885 |
| US-20100173933-A1 | ANTIBACTERIAL AGENTS | ALK, ROS1, NOX1 | TDP1 3078/4885L3MBTL1 703/4885SMN1; SMN2 1208/4885 |
| US-20080275090-A1 | AMINO-BENZAZOLES AS P2Y1 RECEPTOR INHIBITORS WITH PYRIDINE RING AND HETEROCYCLIC COMPONENTS | P2RY1, P2RY11, P2RY2 | TDP1 1894/4885L3MBTL1 4851/4885SMN1; SMN2 3992/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.